# A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer

> **NCT05235906** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 61 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Surufatinib+Sintilimab

## Key facts

- **NCT ID:** NCT05235906
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-16
- **Primary completion:** 2024-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05235906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05235906, "A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05235906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*